Arca
Skip to content
Tools
Tools

IL12A, IL12B: Interleukin-12

Complex in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on IL12A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3

Approved1

  • Ustekinumab

Phase 32

  • Briakinumab
  • Ebdarokimab

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Interleukin-12 inhibitor.
      UstekinumabApprovedJanssen-Cilag Kft.AntibodyInhibitor65
      BriakinumabPhase 3AbbVieAntibodyInhibitor0
      EbdarokimabPhase 3Akeso BiopharmaAntibodyInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Immune Aging and Advanced Therapy Outcomes in Older Adults With IBDUstekinumab—Not yet recruitingFirst Affiliated Hospital, Sun Yat-Sen UniversitySep 18, 2026
      A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical PracticeUstekinumab—RecruitingJanssen-Cilag Kft.Aug 5, 2026
      Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's DiseaseUstekinumab—RecruitingShanghai 10th People's HospitalJul 10, 2026
      FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled TrialUstekinumabPhase 4Not yet recruitingUniversity Hospital, Clermont-FerrandMay 8, 2026
      Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,UstekinumabNot applicableRecruitingCentre Hospitalier Universitaire de NiceApr 14, 2026
      Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper EgyptUstekinumab—Not yet recruitingAssiut UniversityMar 27, 2026
      A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With UstekinumabUstekinumab—RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineMar 23, 2026
      Guselkumab Vs Ustekinumab in Stricturing Crohn's DiseaseUstekinumab—RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineMar 2, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364153, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.